Adverse reaction analysis of drug-induced liver injury
10.12206/j.issn.2097-2024.202404034
- VernacularTitle:药物性肝损伤不良反应分析
- Author:
Yan ZHANG
1
;
Yanjun LI
2
;
Jiahui LIU
2
;
Jiao DENG
2
;
Yuan YUAN
2
;
Jingyi ZHANG
2
Author Information
1. Organ Transplant Department, General Hospital of Northern Theater Command, Shenyang 110016, China.
2. Department of Pharmacy, General Hospital of Northern Theater Command of the PLA, Shenyang 110016, China.
- Publication Type:ColumnfromGeneralHospitalofNorthernTheaterCommand
- Keywords:
drug-induced liver injury;
adverse drug reactions;
Pareto analysis;
medication safety
- From:
Journal of Pharmaceutical Practice and Service
2025;43(1):26-29
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the adverse reaction reports （ADRs） of drug-induced liver injury in recent ten years, explore the characteristics and related rules of drug-induced liver injury, and provide reference for clinical safe drug use. Methods ADRs in our hospital from 2011 to 2021 which belonged to drug-induced liver injuries were collected, and Pareto analysis was carried on. Results In 259 ADR reports, the most common type of drug-induced liver injury was hepatocellular injury （37.84%）. The age of drug-induced liver injury was mainly over 46 years, totaling 195 （75.28%）. Drugs were mainly distributed in cardiovascular system medicine （44.02%）, anti-infective medicine （23.94%）and anti-tumor medicine （11.58%）. Among the cardiovascular drugs, atorvastatin calcium 40mg and over 40mg were the highest proportion, with 53 cases （46.49%）. The main anti-infectious drugs were cephalosporins （29.03%）, carbapenem （19.35%）， antifungal （17.74%）and quinolones （11.29%）. Adverse reactions occurred within 6 days （69.88%）, the duration of adverse reactions was 1-2 weeks （31.66%）, and most patients were improved （47.88%） or cured （37.07%）. Conclusion For middle-aged and elderly patients, when the application of cardiovascular system drugs, anti-infective drugs or anti-tumor drugs, it is necessary to monitor the liver function changes of patients for at least 6 days. If there are abnormalities, the drugs should be stopped or given treatment in time, to avoid the progress of drug-induced liver injury.
